who medicines strategy - libdoc.who.int - World Health Organization

More documents

Recommendations

Info

WHO MEDICINES STRATEGY 2004-2007 | 148of Essential Medicines). Geneva, World Health Organization, 1998 (WHO Technical Report Series No.882).32World pharmaceutical situation survey 1999. World Health Organization. EDM/DAP.33Quick JD. Editorial. Essential medicines twenty-five years on: closing the access gap. Health Policy andPlanning 2003;18(i):1-3.34Guidelines for drug donations.2 nd ed. Interagency guidelines. Geneva, World Health Organization, 1999(WHO/EDM/PAR/99.2).35Guidelines for price discounts of single-source pharmaceuticals. Geneva, World Health Organization,2003 (WHO/EDM/PAR/2003.3).36How to develop and implement a national drug policy, 2 nd ed. Geneva, World Health Organization,2001.37Quick JD et al (eds). Managing drug supply. 2nd ed. West Hartford, Connecticut, Kumarian Press, 1997.38Kaplan WA, Laing R. Is local production of pharmaceuticals a way to improve pharmaceuticalaccess in developing and transitional countries? Setting a research agenda.. Unpublished document.Boston University School of Public Health (http://dcc2.bumc.bu.edu/richardl/RPM+_Project/local_production.htm).39Operational principles for good pharmaceutical procurement. Interagency guidelines. Geneva, WorldHealth Organization, 1999 (WHO/EDM/PAR/99.5).40Quick JD et al (eds). Part III, Section B, Procurement. In: Managing drug supply. 2nd ed. West Hartford,Connecticut, Kumarian Press, 1997.41Surmounting challenges: procurement of antiretroviral medicines in low- and middle-Income countries.Geneva, World Health Organization, Médecins Sans Frontières and Joint United Nations Programme onHIV/AIDS, 2003.42The impact of implementation of ICH guidelines in non-ICH countries. Report of a WHO Meeting.Geneva, 13-15 September 2001. Geneva, World Health Organization, 2002. Regulatory Support Series,No.9 (WHO/EDM/QSM/2002.3).43Quality assurance of pharmaceuticals - A compendium of guidelines and related materials, Vol 1,Geneva, World Health Organization, 1997. Vol 2. Geneva, World Health Organization, 1999.44WHO Expert Committee on Specifications for Pharmaceutical Preparations, 38 th Report. Geneva, WorldHealth Organization 2004 (Technical Report Series No. 908).45The international pharmacopoeia, 3 rd ed., Vol. 1-5. Geneva, World Health Organization, 2003.46Guidelines for the WHO review of dependence-producing psychoactive substances for internationalcontrol. Geneva, World Health Organization, 2000 (WHO/EDM/QSM/2000.5).47Achieving balance in national opioids control policy: Guidelines for assessment. Geneva, World HealthOrganization, 2000 (WHO/EDM/QSM/2000.4).48Report of the International Narcotics Control Board for 2002. Vienna, United Nations, 2002 (E/INCB/2002/1).49Effective drug regulation: what can countries do? Theme paper for discussion. Geneva, World HealthOrganization, 1999 (WHO/HTP/EDM/Mac (11)99.6).50Annual report 2001 - Essential Drugs and Medicines Policy: Extending the evidence base. Geneva,World Health Organization, 2002.51ibid.52Effective medicines regulation: ensuring safety, efficacy and quality. Geneva, WHO Policy Perspectiveson Medicines, No.7. Geneva, World Health Organization, 2003 (WHO/EDM/2003.2).53Reggi V et al. Prescribing information in 26 countries: a comparative study. European Journal of ClinicalPharmacology, Aug 2003; 59(4):263-70.54Ratanwijitrasin S, Wondemagegnehu E. Effective drug regulation - A multicountry study, and Annex 1:Guide for data collection to assess drug regulatory performance. Geneva, World Health Organization,2002.55Quick JD. Ensuring access to essential medicines in developing countries – A framework for action.Geneva, World Health Organization. Presentation at the 25 th Anniversary of Essential MedicinesSeminar, Geneva, 21 October 2002.56The selection and use of essential medicines. Report of the WHO Expert Committee 2002 (including the
REFERENCES | 14912 th Model List of Essential Medicines). Geneva, World Health Organization (WHO Technical ReportSeries No. 914).57Adherence to long-term therapies: evidence for action. Geneva, World Health Organization, 2003.(http://www.who.int/chronic_conditions/adherencereport/en/).58The selection and use of essential medicines. Report of the WHO Expert Committee 2002 (includingthe 12 th Model List of Essential Medicines). Geneva, World Health Organization, 2003 (WHO TechnicalReport Series No. 914).59WHO Model Formulary 2002. Geneva, World Health Organization, 2002.60WHO/EDM medicines website: http://www.who.int/medicines/61Rosenthal MB et al. Promotion of prescription drugs to consumers. New England Journal of Medicine,2002, 346:498-505.62New WHO/NGO database on drug promotion launched. Essential Drugs Monitor, 2002, 31:18.63Ethical criteria for medicinal drug promotion. Geneva, World Health Organization,1988.64Hogerzeil H. Promoting rational prescribing. British Journal of Clinical Pharmacology, 1995;39:1-6.65Quick JD et al., eds. Chapter 29 Investigating drug use. In: Managing drug supply, 2 nd ed. WestHartford, Connecticut, Kumarian Press, 1997 (page 437).66WHA51.17 (1998) World Health Assembly Resolution. Emerging and other communicable diseases:antimicrobial resistance; WHA54.14 (2001) World Health Assembly Resolution. Strengthening healthsystems in developing countries; EM/RC49/R.10 (2002) WHO Regional Committee for the EasternMediterranean Region. Antimicrobial resistance and rational use of antimicrobial agents; WPR/RC53.R5(2002) WHO Regional Committee for the Western Pacific Region. Antimicrobial resistance.67WHO Global strategy for containment of antimicrobial resistance. Geneva, World Health Organization,2001 (WHO/CDS/CSR/DRS/2001.2).68Pharmaceuticals and health sector reform in the Americas: an economic perspective. Washington DC,World Health Organization and Pan American Health Organization, 1998.69Promoting rational use of medicines. WHO Policy Perspectives on Medicine, No. 5. Geneva, WorldHealth Organization, 2002 (WHO/EDM/2002.3).70Annual report 2002. Op. cit.
Page 10 and 11:
WHO MEDICINES STRATEGY 2004-2007 |x
Page 12 and 13:
WHO MEDICINES STRATEGY 2004-2007 |x
Page 14 and 15:
WHO MEDICINES STRATEGY 2004-2007 |
Page 23:
MEDICINESAND PUBLIC HEALTH
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111: WHO MEDICINES STRATEGY 2004-2007 |
Page 157 and 158: REFERENCES
Page 159: REFERENCES | 1471Annual report 2000
show all

who medicines strategy - libdoc.who.int - World Health Organization

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?